<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): September 13, 2000
AXYS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-22788 22-2969941
---------------------------- ------------------------ ----------------------
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of Incorporation) Identification Number)
180 Kimball Way
South San Francisco, CA 94080
---------------------------------------------------
(Address of principal executive offices) (Zip Code)
(650) 829-1000
----------------------------------------------------
(Registrant's telephone number, including area code)
<PAGE> 2
ITEM 5. OTHER EVENTS
In a press release dated September 13, 2000, Axys
Pharmaceuticals, Inc. (the "Company") announced that it is filing a supplement
to its shelf registration statement with the Securities and Exchange Commission
for a public offering of up to $20,000,000 aggregate principal amount of a new
series of fixed rate convertible notes and warrants to purchase shares of its
common stock. The press release, forms of certain agreements relating to the
public offering, the consolidated financial statements of Discovery Partners
International, Inc., in which the Company owns a minority interest, and the
interim financial statements of Discovery Partners International, Inc. for the
quarter ended June 30, 2000 are filed herewith as exhibits.
ITEM 7. Financial Statements, Pro Forma Financial Information and
Exhibits.
(c) Exhibits: The following exhibits are filed as part of this Report.
1.1 Form of Note Purchase Agreement
4.1 Form of Indenture
4.2 Form of Supplemental Indenture
4.3 Form of Common Stock Purchase Warrant
20.1 Press Release, dated September 13, 2000, of Axys
Pharmaceuticals, Inc.
20.2 Consolidated financial statements of Discovery Partners
International, Inc.
20.3 Interim financial statements of Discovery Partners
International, Inc.
23.1 Consent of Ernst & Young, LLP, independent auditors
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrants have duly caused this report to be signed on their behalf by the
undersigned hereunto duly authorized.
Dated: September 13, 2000
AXYS PHARMACEUTICALS, INC.
By: /s/ William J. Newell
--------------------------------------
William J. Newell
Senior Vice President
